{
    "id": 4230,
    "name": "smooth muscle cancer",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:4230",
    "evidence": [
        {
            "id": 16305,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk and Erk phosphorylation in smooth muscle cells expressing KANK2-ALK in culture, resulted in tumor regression and prolonged survival in cell line xenograft models (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 869,
                "therapyName": "Lorlatinib",
                "synonyms": null
            },
            "indication": {
                "id": 4230,
                "name": "smooth muscle cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16306,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Lorbrena (lorlatinib) inhibited Alk and Erk phosphorylation in smooth muscle cells expressing KANK2-ALK in culture, resulted in modest improvement of survival in cell line xenograft models (PMID: 30518629).",
            "molecularProfile": {
                "id": 31582,
                "profileName": "KANK2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 4230,
                "name": "smooth muscle cancer",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14378,
                    "pubMedId": 30518629,
                    "title": "Discovery and Characterization of Recurrent, Targetable ALK Fusions in Leiomyosarcoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30518629"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}